All In Biotech

Drug Trial Radar · NCT05858788

A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.

A Phase 1, Open Label, 3-treatment Period, 1-sequence, Cross-over Study to Evaluate Pharmacokinetics, Safety, and Tolerability After Single Ascending Oral Doses of SAR441566 in Healthy Adult Japanese Male Participants.

Last checked: Nov 19, 2026Latest source record: Sep 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

May 15, 2023

Primary completion

Jul 17, 2023

Study completion Jul 17, 2023

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
May 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a cross-over, Phase 1, 3-treatment period single sequence study. The purpose of this study is to characterize pharmacokinetics (PK), safety, and tolerability of single ascending oral doses of SAR441566 in healthy male Japanese participants, 18-55 years of age.

Conditions

  • Rheumatoid Arthritis

Interventions

  • SAR441566Drug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of plasma pharmacokinetic (PK) parameters for SAR441566: CmaxTime frame: From Day 1 to Day 5 of each period (5 days per period)
  2. Assessment of plasma pharmacokinetic (PK) parameters for SAR441566: AUClastTime frame: From Day 1 to Day 5 of each period (5 days per period)
  3. Assessment of plasma pharmacokinetic (PK) parameters for SAR441566: AUCTime frame: From Day 1 to Day 5 of each period (5 days per period)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parexel International-Site Number:8400001

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.